These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11777323)

  • 1. Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients.
    Vlassopoulos D; Sonikian M; Dardioti V; Pani I; Hadjilouka-Mantaka A; Hadjiconstantinou V
    Ren Fail; 2001 Nov; 23(6):833-42. PubMed ID: 11777323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is spironolactone safe for dialysis patients?
    Hussain S; Dreyfus DE; Marcus RJ; Biederman RW; McGill RL
    Nephrol Dial Transplant; 2003 Nov; 18(11):2364-8. PubMed ID: 14551367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients.
    Michea L; Vukusich A; González M; Zehnder C; Marusic ET
    Kidney Int; 2004 Oct; 66(4):1647-53. PubMed ID: 15458462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a simultaneous potassium and carbohydrate load on extrarenal K homeostasis in end-stage renal failure.
    Alvo M; Krsulovic P; Fernández V; Espinoza AM; Escobar M; Marusic ET
    Nephron; 1989; 53(2):133-7. PubMed ID: 2682302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea.
    Wenzl HH; Fine KD; Santa Ana CA; Porter JL; Fordtran JS
    Dig Dis Sci; 1997 Jan; 42(1):119-28. PubMed ID: 9009126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients.
    Kim HJ
    Nephron; 1996; 72(3):476-82. PubMed ID: 8852501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta adrenergic modulation of extrarenal potassium disposal in terminal uraemia.
    Martinez Vea A; Montoliu J; Andreu L; Torras A; Gaya J; López-Pedret J; Revert L
    Proc Eur Dial Transplant Assoc; 1983; 19():756-60. PubMed ID: 6136035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral glucose administration on serum potassium concentration in hemodialysis patients.
    Muto S; Sebata K; Watanabe H; Shoji F; Yamamoto Y; Ohashi M; Yamada T; Matsumoto H; Mukouyama T; Yonekura T; Namiki S; Kusano E
    Am J Kidney Dis; 2005 Oct; 46(4):697-705. PubMed ID: 16183425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrarenal potassium homeostasis with maximal exercise in end-stage renal disease.
    Clark BA; Shannon C; Brown RS; Gervino EV
    J Am Soc Nephrol; 1996 Aug; 7(8):1223-7. PubMed ID: 8866416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired extrarenal disposal of an acute oral potassium load in patients with endstage renal disease on chronic hemodialysis.
    Fernandez J; Oster JR; Perez GO
    Miner Electrolyte Metab; 1986; 12(2):125-9. PubMed ID: 3960016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease.
    Allon M; Dansby L; Shanklin N
    Am J Med; 1993 May; 94(5):475-482. PubMed ID: 8498392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure].
    Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
    Rinsho Shinkeigaku; 2000 May; 40(5):439-45. PubMed ID: 11002725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of aldosterone in potassium tolerance: studies in anephric humans.
    Sugarman A; Brown RS
    Kidney Int; 1988 Sep; 34(3):397-403. PubMed ID: 3172648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of atrial natriuretic peptide (ANP) during mineralocorticoid escape in normal man.
    Wambach G; Götz S; Suckau G; Kaufmann W
    Klin Wochenschr; 1986; 64 Suppl 6():53-7. PubMed ID: 2948064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone.
    Arrizabalaga P; Montoliu J; Martinez Vea A; Andreu L; López Pedret J; Revert L
    Proc Eur Dial Transplant Assoc; 1983; 20():572-6. PubMed ID: 6318223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis.
    Furuya R; Kumagai H; Sakao T; Maruyama Y; Hishida A
    Nephron; 2002; 92(3):576-81. PubMed ID: 12372940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OACE inhibition does not interfere with acute extrarenal or renal potassium disposal in chronic renal failure.
    Zwettler U; Fliser D; Nowicki M; Ritz E
    Eur J Clin Pharmacol; 1994; 46(3):185-9. PubMed ID: 8070497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-adrenergic-mediated extrarenal potassium disposal in patients with end-stage renal disease: effect of propranolol.
    Yang WC; Huang TP; Ho LT; Chung HM; Chan YL; Batlle DC
    Miner Electrolyte Metab; 1986; 12(3):186-93. PubMed ID: 2873504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The regulation of plasma aldosterone in hemodialysis patients].
    Louis F; Zwahlen A; Favre H; Vallotton M
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1882-4. PubMed ID: 7006078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-charged dialysate for children on hemodialysis: acute dialytic changes.
    Fischbach M; Terzic J; Bitoun Cohen C; Cousandier E; Hamel G; Battouche D; Geisert J
    Pediatr Nephrol; 1998 Jan; 12(1):60-2. PubMed ID: 9502570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.